The EU Commission clears merger of generic Big Pharma company with a competitor’s generic division, subject to the divestment of business for certain generic medicines (Mylan / Upjohn)

Mergers: Commission approves the merger of Mylan and Pfizer's Upjohn division, subject to conditions* The European Commission has approved, under the EU Merger Regulation, the proposed merger between the global pharmaceutical company Mylan and Upjohn, a business division of Pfizer, which operates Pfizer's off-patent branded and generic established medicines. The decision is conditional on the divestment of Mylan's business for certain generic medicines. The transaction will lead to the combination of Mylan, one of the top five generic suppliers in the EEA with the originator Upjohn, whose products have lost exclusivity following patent expiries. Executive Vice-President Margrethe Vestager, responsible for competition policy, said: "Ensuring that patients and hospitals have access

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

European Commission, The EU Commission clears merger of generic Big Pharma company with a competitor’s generic division, subject to the divestment of business for certain generic medicines (Mylan / Upjohn), 22 April 2020, e-Competitions Merger Remedies, Art. N° 94577

Visites 140

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues